STAT3 and hepatocellular carcinoma: Studies have demonstrated the therapeutic properties of DBAs, including as anticancer agents, by inhibiting STAT3 signaling, an oncogenic transcription factor that controls the expression of genes associated with oncogenesis and malignant progression in preclinical models of hepatocellular carcinoma (HCC) and multiple myeloma (MM) [18].